<!DOCTYPE html><html lang="en" ><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8"><meta name="theme-color" media="(prefers-color-scheme: light)" content="#f7f7f7"><meta name="theme-color" media="(prefers-color-scheme: dark)" content="#1b1b1e"><meta name="apple-mobile-web-app-capable" content="yes"><meta name="apple-mobile-web-app-status-bar-style" content="black-translucent"><meta name="viewport" content="width=device-width, user-scalable=no initial-scale=1, shrink-to-fit=no, viewport-fit=cover" ><meta name="generator" content="Jekyll v4.3.2" /><meta property="og:title" content="Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1" /><meta property="og:locale" content="en" /><meta name="description" content="Objectives" /><meta property="og:description" content="Objectives" /><link rel="canonical" href="https://clinicaltree.github.io/posts/volumetric-mri-analysis-of-plexiform-neurofibromas-in-neurofibromatosis-type-1/" /><meta property="og:url" content="https://clinicaltree.github.io/posts/volumetric-mri-analysis-of-plexiform-neurofibromas-in-neurofibromatosis-type-1/" /><meta property="og:site_name" content="Radiology Tree" /><meta property="og:type" content="article" /><meta property="article:published_time" content="2018-01-31T17:00:00+00:00" /><meta name="twitter:card" content="summary" /><meta property="twitter:title" content="Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1" /><meta name="twitter:site" content="@twitter_username" /><meta name="google-site-verification" content="RFHVRgQqK0eGjftEMCTDhsDrR8cJ_ZYcfCX52gXW8KM" /> <script type="application/ld+json"> {"@context":"https://schema.org","@type":"BlogPosting","dateModified":"2023-04-10T03:59:08+00:00","datePublished":"2018-01-31T17:00:00+00:00","description":"Objectives","headline":"Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1","mainEntityOfPage":{"@type":"WebPage","@id":"https://clinicaltree.github.io/posts/volumetric-mri-analysis-of-plexiform-neurofibromas-in-neurofibromatosis-type-1/"},"url":"https://clinicaltree.github.io/posts/volumetric-mri-analysis-of-plexiform-neurofibromas-in-neurofibromatosis-type-1/"}</script><title>Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1 | Radiology Tree</title><link rel="apple-touch-icon" sizes="180x180" href="/assets/img/favicons/apple-touch-icon.png"><link rel="icon" type="image/png" sizes="32x32" href="/assets/img/favicons/favicon-32x32.png"><link rel="icon" type="image/png" sizes="16x16" href="/assets/img/favicons/favicon-16x16.png"><link rel="manifest" href="/assets/img/favicons/site.webmanifest"><link rel="shortcut icon" href="/assets/img/favicons/favicon.ico"><meta name="apple-mobile-web-app-title" content="Radiology Tree"><meta name="application-name" content="Radiology Tree"><meta name="msapplication-TileColor" content="#da532c"><meta name="msapplication-config" content="/assets/img/favicons/browserconfig.xml"><meta name="theme-color" content="#ffffff"><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://fonts.gstatic.com" crossorigin><link rel="dns-prefetch" href="https://fonts.gstatic.com" crossorigin><link rel="preconnect" href="https://fonts.googleapis.com" ><link rel="dns-prefetch" href="https://fonts.googleapis.com" ><link rel="preconnect" href="https://cdn.jsdelivr.net" ><link rel="dns-prefetch" href="https://cdn.jsdelivr.net" ><link rel="stylesheet" href="https://fonts.googleapis.com/css2?family=Lato&family=Source+Sans+Pro:wght@400;600;700;900&display=swap"><link rel="preconnect" href="https://www.google-analytics.com" crossorigin="use-credentials"><link rel="dns-prefetch" href="https://www.google-analytics.com"><link rel="preconnect" href="https://www.googletagmanager.com" crossorigin="anonymous"><link rel="dns-prefetch" href="https://www.googletagmanager.com"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/css/bootstrap.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/@fortawesome/fontawesome-free@6.2.1/css/all.min.css"><link rel="stylesheet" href="/assets/css/style.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.css"><link rel="stylesheet" href="https://cdn.jsdelivr.net/npm/magnific-popup@1.1.0/dist/magnific-popup.min.css"> <script src="https://cdn.jsdelivr.net/npm/jquery@3.6.1/dist/jquery.min.js"></script> <script type="text/javascript"> class ModeToggle { static get MODE_KEY() { return "mode"; } static get MODE_ATTR() { return "data-mode"; } static get DARK_MODE() { return "dark"; } static get LIGHT_MODE() { return "light"; } static get ID() { return "mode-toggle"; } constructor() { if (this.hasMode) { if (this.isDarkMode) { if (!this.isSysDarkPrefer) { this.setDark(); } } else { if (this.isSysDarkPrefer) { this.setLight(); } } } let self = this; /* always follow the system prefers */ this.sysDarkPrefers.addEventListener('change', () => { if (self.hasMode) { if (self.isDarkMode) { if (!self.isSysDarkPrefer) { self.setDark(); } } else { if (self.isSysDarkPrefer) { self.setLight(); } } self.clearMode(); } self.notify(); }); } /* constructor() */ get sysDarkPrefers() { return window.matchMedia("(prefers-color-scheme: dark)"); } get isSysDarkPrefer() { return this.sysDarkPrefers.matches; } get isDarkMode() { return this.mode === ModeToggle.DARK_MODE; } get isLightMode() { return this.mode === ModeToggle.LIGHT_MODE; } get hasMode() { return this.mode != null; } get mode() { return sessionStorage.getItem(ModeToggle.MODE_KEY); } /* get the current mode on screen */ get modeStatus() { if (this.isDarkMode || (!this.hasMode && this.isSysDarkPrefer)) { return ModeToggle.DARK_MODE; } else { return ModeToggle.LIGHT_MODE; } } setDark() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.DARK_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.DARK_MODE); } setLight() { $('html').attr(ModeToggle.MODE_ATTR, ModeToggle.LIGHT_MODE); sessionStorage.setItem(ModeToggle.MODE_KEY, ModeToggle.LIGHT_MODE); } clearMode() { $('html').removeAttr(ModeToggle.MODE_ATTR); sessionStorage.removeItem(ModeToggle.MODE_KEY); } /* Notify another plugins that the theme mode has changed */ notify() { window.postMessage({ direction: ModeToggle.ID, message: this.modeStatus }, "*"); } flipMode() { if (this.hasMode) { if (this.isSysDarkPrefer) { if (this.isLightMode) { this.clearMode(); } else { this.setLight(); } } else { if (this.isDarkMode) { this.clearMode(); } else { this.setDark(); } } } else { if (this.isSysDarkPrefer) { this.setLight(); } else { this.setDark(); } } this.notify(); } /* flipMode() */ } /* ModeToggle */ const modeToggle = new ModeToggle(); </script><body data-topbar-visible="true"><div id="sidebar" class="d-flex flex-column align-items-end"><div class="profile-wrapper text-center"><div id="avatar"> <a href="/" class="mx-auto"> <img src="https://storage.googleapis.com/clinicalpub.com/images/favicon.png" alt="avatar" onerror="this.style.display='none'"> </a></div><div class="site-title"> <a href="/">Radiology Tree</a></div><div class="site-subtitle font-italic">Update every day the best and the lastest articles, books, journals, clinical cases, videos, images... for radiologist</div></div><ul class="w-100"><li class="nav-item"> <a href="/" class="nav-link"> <i class="fa-fw fas fa-home ml-xl-3 mr-xl-3 unloaded"></i> <span>HOME</span> </a><li class="nav-item"> <a href="/categories/" class="nav-link"> <i class="fa-fw fas fa-stream ml-xl-3 mr-xl-3 unloaded"></i> <span>CATEGORIES</span> </a><li class="nav-item"> <a href="/tags/" class="nav-link"> <i class="fa-fw fas fa-tag ml-xl-3 mr-xl-3 unloaded"></i> <span>TAGS</span> </a><li class="nav-item"> <a href="/archives/" class="nav-link"> <i class="fa-fw fas fa-archive ml-xl-3 mr-xl-3 unloaded"></i> <span>ARCHIVES</span> </a><li class="nav-item"> <a href="/about/" class="nav-link"> <i class="fa-fw fas fa-info-circle ml-xl-3 mr-xl-3 unloaded"></i> <span>ABOUT</span> </a></ul><div class="sidebar-bottom mt-auto d-flex flex-wrap justify-content-center align-items-center"> <button class="mode-toggle btn" aria-label="Switch Mode"> <i class="fas fa-adjust"></i> </button> <span class="icon-border"></span> <a href="https://github.com/clinicaltree" aria-label="github" target="_blank" rel="noopener noreferrer"> <i class="fab fa-github"></i> </a> <a href="https://twitter.com/twitter_username" aria-label="twitter" target="_blank" rel="noopener noreferrer"> <i class="fab fa-twitter"></i> </a> <a href="javascript:location.href = 'mailto:' + ['clinicalpub.team','gmail.com'].join('@')" aria-label="email" > <i class="fas fa-envelope"></i> </a> <a href="/feed.xml" aria-label="rss" > <i class="fas fa-rss"></i> </a></div></div><div id="topbar-wrapper"><div id="topbar" class="container d-flex align-items-center justify-content-between h-100 pl-3 pr-3 pl-md-4 pr-md-4"> <span id="breadcrumb"> <span> <a href="/"> Home </a> </span> <span>Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1</span> </span> <i id="sidebar-trigger" class="fas fa-bars fa-fw"></i><div id="topbar-title"> Post</div><i id="search-trigger" class="fas fa-search fa-fw"></i> <span id="search-wrapper" class="align-items-center"> <i class="fas fa-search fa-fw"></i> <input class="form-control" id="search-input" type="search" aria-label="search" autocomplete="off" placeholder="Search..."> </span> <span id="search-cancel" >Cancel</span></div></div><div id="main-wrapper" class="d-flex justify-content-center"><div id="main" class="container pl-xl-4 pr-xl-4"><div class="row"><div id="core-wrapper" class="col-12 col-lg-11 col-xl-9 pr-xl-4"><div class="post pl-1 pr-1 pl-md-2 pr-md-2"><h1 data-toc-skip>Volumetric MRI Analysis of Plexiform Neurofibromas in Neurofibromatosis Type 1</h1><div class="post-meta text-muted"> <span> Posted <em class="" data-ts="1517418000" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Jan 31, 2018 </em> </span> <span> Updated <em class="" data-ts="1681099148" data-df="ll" data-toggle="tooltip" data-placement="bottom"> Apr 10, 2023 </em> </span><div class="d-flex justify-content-between"> <span> By <em> <a href="">Wenli Cai PhD</a> </em>, <em> <a href="">Seth M. Steinberg PhD</a> </em>, <em> <a href="">Miriam A. Bredella MD</a> </em>, <em> <a href="">Gina Basinsky MD</a> </em>, <em> <a href="">Bhanusupriya Somarouthu MD</a> </em>, <em> <a href="">Scott R. Plotkin MD PhD</a> </em>, <em> <a href="">Jeffrey Solomon PhD</a> </em>, <em> <a href="">Brigitte C. Widemann MD</a> </em>, <em> <a href="">Gordon J. Harris PhD</a> </em>, <em> <a href="">Eva Dombi MD</a> </em> </span><div> <span class="readtime" data-toggle="tooltip" data-placement="bottom" title="2352 words"> <em>13 min</em> read</span></div></div></div><div class="post-content"><h2 id="objectives"><span class="mr-2">Objectives</span><a href="#objectives" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Plexiform neurofibromas (PNs) are complex, histologically benign peripheral nerve sheath tumors that are challenging to measure by simple line measurements. Computer-aided volumetric segmentation of PN has become the recommended method to assess response in clinical trials directed at PN. Different methods for volumetric analysis of PN have been developed. The goal of this study is to test the level of agreement in volume measurements and in interval changes using two separate methods of volumetric magnetic resonance imaging analysis.</p><h2 id="methods"><span class="mr-2">Methods</span><a href="#methods" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Three independent volume measurements were performed on 15 PN imaged at three time-points using 3DQI software at Massachusetts General Hospital (MGH) and National Cancer Institute (NCI) and MEDx software at NCI.</p><h2 id="results"><span class="mr-2">Results</span><a href="#results" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Median volume differences at each time-point comparing MGH-3DQI and NCI-3DQI were −0.5, −4.2, and −19.9 mL; comparing NCI-3DQI and NCI-MEDx were −21.0, −47.0, and −21.0 mL; comparing MGH-3DQI and NCI-MEDx were −10.0, −70.3, and −29.9 mL. Median differences in percentage change over time comparing MGH-3DQI and NCI-3DQI were −1.7, 1.1, and −1.0%; comparing NCI-3DQI and NCI-MEDx were −2.3, 3.3, and −1.1%; comparing MGH-3DQI and NCI-MEDx were −0.4, 2.0, and −1.5%. Volume differences were &lt;20% of the mean of the two measurements in 117 of 135 comparisons (86.7%). Difference in interval change was &lt;20% in 120 of the 135 comparisons (88.9%), while disease status classification was concordant in 115 of 135 comparisons (85.2%).</p><h2 id="conclusions"><span class="mr-2">Conclusions</span><a href="#conclusions" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>The volumes, interval changes, and progression status classifications were in good agreement. The comparison of two volumetric analysis methods suggests no systematic differences in tumor assessment. A prospective comparison of the two methods is planned.</p><h2 id="introduction"><span class="mr-2">Introduction</span><a href="#introduction" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p>Plexiform neurofibromas (PNs) are histologically benign nerve sheath tumors typically associated with neurofibromatosis type-1 (NF1). These tumors develop along multiple branches of peripheral nerves and can be large, or irregularly shaped, making standard linear measurements unreliable. PNs are well visualized by magnetic resonance imaging (MRI) using short tau inversion recovery (STIR) sequence, and can be contoured using computer-aided volumetric lesion segmentation methods . Volumetric evaluation has become the method of choice to determine tumor response and time to disease progression in recent clinical trials for NF1-related PNs .</p><p>In the phase 1 trial of the MEK inhibitor selumetinib, 71% of patients with inoperable PN experienced at least 20% volume reduction, and in some cases, improvement in clinical symptoms . If the ongoing phase 2 trial confirms a similar response rate and proves that the moderate size decreases are indeed associated with clinical improvement, selumetinib may become the first medical therapy approved by the US Food and Drug Administration (FDA) for the treatment of PN.</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="methods-1"><span class="mr-2">Methods</span><a href="#methods-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><h2 id="patients"><span class="mr-2">Patients</span><a href="#patients" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="mri-acquisition"><span class="mr-2">MRI Acquisition</span><a href="#mri-acquisition" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="image-analysis"><span class="mr-2">Image Analysis</span><a href="#image-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="statistical-analysis"><span class="mr-2">Statistical Analysis</span><a href="#statistical-analysis" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="results-1"><span class="mr-2">Results</span><a href="#results-1" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/VolumetricMRIAnalysisofPlexiformNeurofibromasinNeurofibromatosisType1/0_1s20S1076633217303914.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/VolumetricMRIAnalysisofPlexiformNeurofibromasinNeurofibromatosisType1/0_1s20S1076633217303914.jpg" alt="Figure 1, Examples of plexiform neurofibromas included in the study. Coronal ( top row ) and axial ( second row ) STIR MR images of PN included in the study. PN 4: small, well-defined PN in the right lumbar paraspinal muscle layer. PN 5: large and highly complex PN in the upper chest, left shoulder, and arm. PN 10: medium-sized right neck PN with moderately complex shape. PN 12: medium-sized PN in left face, infiltrating the orbit, and facial muscles. PN 15: coronal overview and segmentation contours at comparable levels in the axial plane from the three volumetric analyses, as labeled. PN, plexiform neurofibromas; STIR MR, short tau inversion recovery magnetic resonance." class="lazyload" data-proofer-ignore></a></p><p>Table 1</p><p>Three Independent Volumetric MRI Measurements of 15 PN Imaged at Three Different Time-points</p><p>ID PN Location Time-point 1 MRI Time-point 2 MRI Time-point 3 MRI MGH-3DQI NCI-3DQI NCI-MEDx MGH-3DQI NCI-3DQI NCI-MEDx MGH-3DQI NCI-3DQI NCI-MEDx 1 Abdomen 2568.7 3013 3302 4204.5 4127 4533 4724.3 4930 5150 2 Neck, chest 588.2 599 647 682.7 674 753 743.6 746 818 3 Neck, chest 893.0 824 892 1112.1 1087 1244 1399.5 1380 1425 4 Back 129.4 126 147 137.3 135 150 151.7 149 170 5 Brachial plexus 359.0 444 591 421.1 514 659 527.6 657 771 6 Chest 1861.3 1856 1838 1938.9 1964 2030 2253.1 2273 2283 7 Chest, left arm 1243.0 1426 1564 1377.9 1690 1820 1880.8 2060 2287 8 Face 180.1 155 177 175.7 173 181 204.8 194 201 9 Lower leg 255.4 285 270 299.1 329 328 270.5 303 290 10 Neck 152.0 151 162 175.8 180 188 257.7 256 288 11 Orbit 91.8 88.3 87.8 82.2 96.7 106 63.0 76.7 79.3 12 Orbit, face 175.1 180 168 211.4 201 194 241.9 200 194 13 Pelvis 987.5 988 970 993.8 1086 1133 1098.5 1146 1196 14 Abdomen, pelvis 1021.2 868 836 1634.6 1311 1282 2864.1 2949 2835 15 Pelvis, thigh 1755.2 1859 2068 2867.2 3081 3195 3134.1 3902 3916</p><p>MGH, Massachusetts General Hospital; MRI, magnetic resonance imaging; NCI, National Cancer Institute; PN, plexiform neurofibroma.</p><p>The customary reporting style at MGH is to give all values with decimals, whereas at NCI volumes over 100 mL are rounded to the nearest whole. The smallest volume in the dataset is 63.0 mL (PN11, MGH-3DQI, time-point 3), and the largest volume is 5150 mL (PN1, NCI-MEDx, time-point 3). Volume trends by age are provided in Supplementary Fig S1 .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Table 2</p><p>Summary of Volume Measurement Differences</p><p>A. Volumes Time-point 1 MRI Time-point 2 MRI Time-point 3 MRI MGH-3DQI—NCI-3DQI Volume difference:</p><p>Median (range) mL* −0.5</p><p>(−444.3 to 153.2)</p><p><em>P</em> = .45 −4.2</p><p>(−312.1 to 323.6)</p><p><em>P</em> = .42 −19.9</p><p>(−767.9 to 41.9)</p><p><em>P</em> = .035 *Corresponding relative volume difference—% of mean (PN ID) 0.1 (PN13)</p><p>15.9 (PN1); 16.2 (PN14) 2.4 (PN10)</p><p>20.3 (PN7); 22.0 (PN14) 0.9 (PN6)</p><p>21.8 (PN15); 19.0 (PN12) Relative volume difference</p><p>Median (range)—% of mean** 5.7</p><p>(0.1–21.2) 5.0</p><p>(1.3–22.0) 4.3</p><p>(0.3–21.8) **Corresponding absolute volume difference—mL (PN ID) 103.8 (PN15)</p><p>0.5 (PN13); 85.0 (PN5) 10.4 (PN12)</p><p>8.7 (PN2); 323.6 (PN14) 205.7 (PN1)</p><p>2.4 (PN2); 767.9 (PN15) Number of PN with &lt;20% relative volume difference 14 13 13 NCI-3DQI—NCI-MEDx Volume difference:</p><p>Median (range)—mL* −21.0</p><p>(−289.0 to 32.0)</p><p><em>P</em> = .071 −47.0</p><p>(−406.0 to 29.0)</p><p><em>P</em> = .0024 −21.0</p><p>(−227.0 to 114.0)</p><p><em>P</em> = .018 *Corresponding relative volume difference—% of mean (PN ID) 15.4 (PN4)</p><p>9.2 (PN1); 3.8 (PN14) 4.2 (PN13)</p><p>24.7 (PN1); 2.2 (PN14) 13.2 (PN4)</p><p>10.4 (PN7); 3.9 (PN14) Relative volume difference</p><p>Median (range)—% of mean** 7.7</p><p>(0.6–28.4) 4.5</p><p>(0.3–24.7) 4.3</p><p>(0.4–16.0) **Corresponding absolute volume difference—mL (PN ID) 48.0 (PN2)</p><p>0.5 (PN11); 147.0 (PN5) 8.0 (PN8)</p><p>1.0 (PN9); 145.0 (PN5) 50.0 (PN13)</p><p>10.0 (PN6); 114.0 (PN5) Number of PN with &lt;20% relative volume difference 14 14 15 MGH-3DQI—NCI-MEDx Volume difference:</p><p>Median (range)—mL* −10.0</p><p>(−733.3 to 185.2)</p><p><em>P</em> = .21 −70.3</p><p>(−442.1 to 352.6)</p><p><em>P</em> = .015 −29.9</p><p>(−781.9 to 47.9)</p><p><em>P</em> = .010 *Corresponding relative volume difference—% of mean (PN ID) 6.4 (PN10)</p><p>25.0 (PN1); 19.9 (PN14) 9.8 (PN2)</p><p>27.6 (PN7); 24.2 (PN14) 1.3 (PN6)</p><p>22.2 (PN15); 22.0 (PN12) Relative volume difference</p><p>Median (range)—% of mean** 6.4</p><p>(0.1–48.8) 9.8</p><p>(3.0–44.0) 9.5</p><p>(1.0–37.5) **Corresponding absolute volume difference—mL (PN ID) 10.0 (PN10)</p><p>1.0 (PN3); 232.0 (PN5) 70.3 (PN2)</p><p>5.3 (PN8); 237.9 (PN5) 74.4 (PN2)</p><p>29.1 (PN14); 243.4 (PN5) Number of PN with &lt;20% relative volume difference 12 11 11</p><p>B. Interval Changes Time-points 1–2 Time-points 2–3 Time-points 1–3 MGH-3DQI—NCI-3DQI Difference in % change</p><p>Median (range)—% −1.7</p><p>(−20.0 to 26.7)</p><p><em>P</em> = .56 1.1</p><p>(−49.7 to 14.9)</p><p><em>P</em> = .80 −1.0</p><p>(−59.3 to 27.0)</p><p><em>P</em> = .27 Largest discrepancy in interval change—% (PN ID) 63.7 vs 37.0</p><p>(PN1) 75.2 vs 124.9</p><p>(PN14) 180.5 vs 239.7</p><p>(PN14) Number of PN with &lt;20% difference in interval change 13 14 11 Number of PN with concordant disease status assessment 14 14 12 NCI-3DQI—NCI-MEDx Difference in % change</p><p>Median (range)—% −2.3</p><p>(−11.2 to 11.2)</p><p><em>P</em> = .60 3.3</p><p>(−11.0 to 12.4),</p><p><em>P</em> = .095 −1.1</p><p>(−8.2 to 20.5)</p><p><em>P</em> = .60 Largest discrepancy in interval change—% (PN ID) 65.7 vs 54.5</p><p>(PN15) 27.0 vs 14.5</p><p>(PN3) 109.9 vs 89.4</p><p>(PN15) Number of PN with &lt;20% difference in interval change 15 15 14 Number of PN with concordant disease status assessment 13 13 13 MGH-3DQI—NCI-MEDx Difference in % change</p><p>Median (range)—% −0.4</p><p>(−31.2 to 26.4)</p><p><em>P</em> = .68 2.0</p><p>(−45.9 to 14.4)</p><p><em>P</em> = .39 −1.5</p><p>(−58.7 to 28.0)</p><p><em>P</em> = .64 Largest discrepancy in interval change—% (PN ID) −10.5 vs 20.7</p><p>(PN11) 75.2 vs 121.1</p><p>(PN14) 180.5 vs 239.1</p><p>(PN14) Number of PN with &lt;20% difference in interval change 13 14 11 Number of PN with concordant disease status assessment 12 12 12</p><p>MGH, Massachusetts General Hospital; MRI, magnetic resonance imaging; NCI, National Cancer Institute; PN ID, plexiform neurofibromas identification.</p><p>In large tumors, absolute volume differences tend to be greater, but in proportion to their size smaller lesions can have more measurement discrepancy; therefore, we provide both the numeric and relative differences. The volume differences were calculated by subtracting one volume from the matching other, as listed in the header, and ranged from −781.9 mL (PN15, MGH3DQI vs NCI-MEDx, time-point 3) to 406.0 mL (PN1, MGH-3DQI vs NCI-3DQI, time-point 2). Relative volume differences were calculated using the absolute volume differences between the matching pairs (irrespective of negative or positive values), and comparing to the mean of the same pairs. PN ID refers to the lesion identification as listed in Table 1 .</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://storage.googleapis.com/dl.dentistrykey.com/clinical/VolumetricMRIAnalysisofPlexiformNeurofibromasinNeurofibromatosisType1/1_1s20S1076633217303914.jpg" class="popup img-link "><img data-src="https://storage.googleapis.com/dl.dentistrykey.com/clinical/VolumetricMRIAnalysisofPlexiformNeurofibromasinNeurofibromatosisType1/1_1s20S1076633217303914.jpg" alt="Figure 2, Bland-Altman plots of percent change differences between time-points. Bland-Altman plots of percent change differences from time-points 1–2 ( left panels ), from time-points 2–3 ( middle panels ), and from time-points 1–3 ( right panels ). Measurement differences are plotted against the averages of the two measurements. The top row compares the results of 3DQI method at MGH to 3DQI method at NCI (same method, different user), middle row compares the results of 3DQI method at NCI to MEDx method at NCI (different method, same user), and bottom row compares the results of 3DQI method at MGH to MEDx method at NCI (different method, different user). MGH, Massachusetts General Hospital; NCI, National Cancer Institute." class="lazyload" data-proofer-ignore></a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="discussion"><span class="mr-2">Discussion</span><a href="#discussion" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="supplementary-data"><span class="mr-2">Supplementary Data</span><a href="#supplementary-data" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Figure S1</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Figure S2</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p>Figure S3</p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><p><a href="https://clinicalpub.com/app">Get Radiology Tree app to read full this article&lt;</a></p><h2 id="references"><span class="mr-2">References</span><a href="#references" class="anchor text-muted"><i class="fas fa-hashtag"></i></a></h2><ul><li><p>1. Cai W., Kassarjian A., Bredella M.A., et. al.: Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology 2009; 250: pp. 665-673.</p><li><p>2. Solomon J., Warren K., Dombi E., et. al.: Automated detection and volume measurement of plexiform neurofibromas in neurofibromatosis 1 using magnetic resonance imaging. Comput Med Imaging Graph 2004; 28: pp. 257-265.</p><li><p>3. Poussaint T.Y., Jaramillo D., Chang Y., et. al.: Interobserver reproducibility of volumetric MR imaging measurements of plexiform neurofibromas. AJR Am J Roentgenol 2003; 180: pp. 419-423.</p><li><p>4. Dombi E., Baldwin A., Marcus L.J., et. al.: Activity of selumetinib in neurofibromatosis type 1-related plexiform neurofibromas. N Engl J Med 2016; 375: pp. 2550-2560.</p><li><p>5. Robertson K.A., Nalepa G., Yang F.C., et. al.: Imatinib mesylate for plexiform neurofibromas in patients with neurofibromatosis type 1: a phase 2 trial. Lancet Oncol 2012; 13: pp. 1218-1224.</p><li><p>6. Weiss B., Widemann B.C., Wolters P., et. al.: Sirolimus for progressive neurofibromatosis type 1-associated plexiform neurofibromas: a neurofibromatosis Clinical Trials Consortium phase II study. Neuro Oncol 2015; 17: pp. 596-603.</p><li><p>7. Weiss B., Widemann B.C., Wolters P., et. al.: Sirolimus for non-progressive NF1-associated plexiform neurofibromas: an NF clinical trials consortium phase II study. Pediatr Blood Cancer 2014; 61: pp. 982-986.</p><li><p>8. Widemann B.C., Babovic-Vuksanovic D., Dombi E., et. al.: Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Pediatr Blood Cancer 2014; 61: pp. 1598-1602.</p><li><p>9. Widemann B.C., Dombi E., Gillespie A., et. al.: Phase 2 randomized, flexible crossover, double-blinded, placebo-controlled trial of the farnesyltransferase inhibitor tipifarnib in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas. Neuro Oncol 2014; 16: pp. 707-718.</p><li><p>10. Plotkin S.R., Blakeley J.O., Dombi E., et. al.: Achieving consensus for clinical trials: the REiNS International Collaboration. Neurology 2013; 81: pp. S1-S5.</p><li><p>11. Dombi E., Ardern-Holmes S.L., Babovic-Vuksanovic D., et. al.: Recommendations for imaging tumor response in neurofibromatosis clinical trials. Neurology 2013; 81: pp. S33-S40.</p><li><p>12. Eisenhauer E.A., Therasse P., Bogaerts J., et. al.: New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: pp. 228-247.</p><li><p>13. Miller A.B., Hoogstraten B., Staquet M., et. al.: Reporting results of cancer treatment. Cancer 1981; 47: pp. 207-214.</p><li><p>14. Zhao B., James L.P., Moskowitz C.S., et. al.: Evaluating variability in tumor measurements from same-day repeat CT scans of patients with non-small cell lung cancer. Radiology 2009; 252: pp. 263-272.</p><li><p>15. Yoon S.H., Kim K.W., Goo J.M., et. al.: Observer variability in RECIST-based tumour burden measurements: a meta-analysis. Eur J Cancer 2016; 53: pp. 5-15.</p><li><p>16. Oxnard G.R., Zhao B., Sima C.S., et. al.: Variability of lung tumor measurements on repeat computed tomography scans taken within 15 minutes. J Clin Oncol 2011; 29: pp. 3114-3119.</p><li><p>17. Ford R., Schwartz L., Dancey J., et. al.: Lessons learned from independent central review. Eur J Cancer 2009; 45: pp. 268-274.</p><li><p>18. Buckler A.J., Danagoulian J., Johnson K., et. al.: Inter-method performance study of tumor volumetry assessment on computed tomography test-retest data. Acad Radiol 2015; 22: pp. 1393-1408.</p><li><p>19. Dejaco D., Url C., Schartinger V.H., et. al.: Approximation of head and neck cancer volumes in contrast enhanced CT. Cancer Imaging 2015; 15: pp. 16.</p><li><p>20. Nishino M., Guo M., Jackman D.M., et. al.: CT tumor volume measurement in advanced non-small-cell lung cancer: performance characteristics of an emerging clinical tool. Acad Radiol 2011; 18: pp. 54-62.</p></ul></div><div class="post-tail-wrapper text-muted"><div class="post-meta mb-3"> <i class="far fa-folder-open fa-fw mr-1"></i> <a href='/categories/academic-radiology/'>Academic Radiology</a>, <a href='/categories/volume-25/'>Volume 25</a>, <a href='/categories/issue-2/'>Issue 2</a></div><div class="post-tags"> <i class="fa fa-tags fa-fw mr-1"></i> <a href="/tags/journals/" class="post-tag no-text-decoration" >Journals</a> <a href="/tags/general-radiology/" class="post-tag no-text-decoration" >General Radiology</a></div><div class="post-tail-bottom d-flex justify-content-between align-items-center mt-3 pt-5 pb-2"><div class="license-wrapper"> This post is licensed under <a href="https://creativecommons.org/licenses/by/4.0/"> CC BY 4.0 </a> by the author.</div><div class="share-wrapper"> <span class="share-label text-muted mr-1">Share</span> <span class="share-icons"> <a href="https://twitter.com/intent/tweet?text=Volumetric%20MRI%20Analysis%20of%20Plexiform%20Neurofibromas%20in%20Neurofibromatosis%20Type%201%20-%20Radiology%20Tree&url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fvolumetric-mri-analysis-of-plexiform-neurofibromas-in-neurofibromatosis-type-1%2F" data-toggle="tooltip" data-placement="top" title="Twitter" target="_blank" rel="noopener" aria-label="Twitter"> <i class="fa-fw fab fa-twitter"></i> </a> <a href="https://www.facebook.com/sharer/sharer.php?title=Volumetric%20MRI%20Analysis%20of%20Plexiform%20Neurofibromas%20in%20Neurofibromatosis%20Type%201%20-%20Radiology%20Tree&u=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fvolumetric-mri-analysis-of-plexiform-neurofibromas-in-neurofibromatosis-type-1%2F" data-toggle="tooltip" data-placement="top" title="Facebook" target="_blank" rel="noopener" aria-label="Facebook"> <i class="fa-fw fab fa-facebook-square"></i> </a> <a href="https://t.me/share/url?url=https%3A%2F%2Fclinicaltree.github.io%2Fposts%2Fvolumetric-mri-analysis-of-plexiform-neurofibromas-in-neurofibromatosis-type-1%2F&text=Volumetric%20MRI%20Analysis%20of%20Plexiform%20Neurofibromas%20in%20Neurofibromatosis%20Type%201%20-%20Radiology%20Tree" data-toggle="tooltip" data-placement="top" title="Telegram" target="_blank" rel="noopener" aria-label="Telegram"> <i class="fa-fw fab fa-telegram"></i> </a> <i id="copy-link" class="fa-fw fas fa-link small" data-toggle="tooltip" data-placement="top" title="Copy link" data-title-succeed="Link copied successfully!"> </i> </span></div></div></div></div></div><div id="panel-wrapper" class="col-xl-3 pl-2 text-muted"><div class="access"><div id="access-lastmod" class="post"><div class="panel-heading">Recently Updated</div><ul class="post-content pl-0 pb-1 ml-1 mt-2"><li><a href="/posts/neurometabolites-alteration-in-the-acute-phase-of-mild-traumatic-brain-injury-mtbi/">Neurometabolites Alteration in the Acute Phase of Mild Traumatic Brain Injury (mTBI)</a><li><a href="/posts/reinforcing-the-importance-and-feasibility-of-implementing-a-low-dose-protocol-for-ct-guided-biopsie/">Reinforcing the Importance and Feasibility of Implementing a Low-dose Protocol for CT-guided Biopsies</a><li><a href="/posts/rethinking-the-pgy-1-basic-clinical-year/">Rethinking the PGY-1 Basic Clinical Year</a><li><a href="/posts/single-injection-dual-phase-cone-beam-ct-dp-cbct-vascular-anatomy-assessment-and-occult-nodule-det/">Single Injection Dual-Phase Cone Beam CT (DP-CBCT) Vascular Anatomy Assessment and Occult Nodule Detection; Have We Reached the Focus?</a><li><a href="/posts/the-yellow-scale-is-superior-to-the-gray-scale-for-detecting-acute-ischemic-stroke-on-a-monitor-disp/">The Yellow Scale Is Superior to the Gray Scale for Detecting Acute Ischemic Stroke on a Monitor Display in Computed Tomography</a></ul></div><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="toc-wrapper" class="pl-0 pr-4 mb-5"><div class="panel-heading pl-3 pt-2 mb-2">Contents</div><nav id="toc"></nav></div><script src="https://cdn.jsdelivr.net/npm/tocbot@4.20.1/dist/tocbot.min.js"></script></div></div><div class="row"><div id="tail-wrapper" class="col-12 col-lg-11 col-xl-9 pl-3 pr-3 pr-xl-4 mt-5"><div id="related-posts" class="mb-2 mb-sm-4"><h3 class="pt-2 mb-4 ml-1" data-toc-skip>Further Reading</h3><div class="card-deck mb-4"><div class="card"> <a href="/posts/accuracy-of-computed-tomographic-enterography-for-obscure-gastrointestinal-bleeding/"><div class="card-body"> <em class="small" data-ts="1517418000" data-df="ll" > Jan 31, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Accuracy of Computed Tomographic Enterography for Obscure Gastrointestinal Bleeding</h3><div class="text-muted small"><p> Rationale and Objectives Obscure gastrointestinal bleeding (OGIB) is the bleeding from the gastrointestinal tract without definite source that persists and recurs after a negative endoscopic evalu...</p></div></div></a></div><div class="card"> <a href="/posts/apparent-diffusion-coefficient-value-to-evaluate-tumor-response-after-neoadjuvant-chemotherapy-in-pa/"><div class="card-body"> <em class="small" data-ts="1517418000" data-df="ll" > Jan 31, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Apparent Diffusion Coefficient Value to Evaluate Tumor Response After Neoadjuvant Chemotherapy in Patients with Breast Cancer</h3><div class="text-muted small"><p> Rationale and Objectives This study explored tumor behavior in patients with breast cancer during neoadjuvant chemotherapy (NAC) by sequential measurements of tumor apparent diffusion coefficient ...</p></div></div></a></div><div class="card"> <a href="/posts/automated-radiology-operative-note-communication-tool-closing-the-loop-in-musculoskeletal-imaging/"><div class="card-body"> <em class="small" data-ts="1517418000" data-df="ll" > Jan 31, 2018 </em><h3 class="pt-0 mt-1 mb-3" data-toc-skip>Automated Radiology-Operative Note Communication Tool; Closing the Loop in Musculoskeletal Imaging</h3><div class="text-muted small"><p> Rationale and Objectives Correlation of imaging studies and reference standard outcomes is a significant challenge in radiology. This study evaluates the effectiveness of a new communication tool ...</p></div></div></a></div></div></div><div class="post-navigation d-flex justify-content-between"> <a href="/posts/virtual-simulation-in-enhancing-procedural-training-for-fluoroscopy-guided-lumbar-puncture/" class="btn btn-outline-primary" prompt="Older"><p>Virtual Simulation in Enhancing Procedural Training for Fluoroscopy-guided Lumbar Puncture</p></a> <a href="/posts/volumetric-mri-in-neurofibromatosis-type-1-nf1-comes-of-age-to-help-determine-initiation-and-monit/" class="btn btn-outline-primary" prompt="Newer"><p>Volumetric MRI in Neurofibromatosis Type 1 (NF1) Comes of Age to Help Determine Initiation and Monitoring of Targeted Therapies for Plexiform Neurofibromas</p></a></div></div></div></div><div id="search-result-wrapper" class="d-flex justify-content-center unloaded"><div class="col-12 col-sm-11 post-content"><div id="search-hints"><div id="access-tags"><div class="panel-heading">Trending Tags</div><div class="d-flex flex-wrap mt-3 mb-1 mr-3"> <a class="post-tag" href="/tags/general-radiology/">General Radiology</a> <a class="post-tag" href="/tags/journals/">Journals</a></div></div></div><div id="search-results" class="d-flex flex-wrap justify-content-center text-muted mt-3"></div></div></div></div><footer><div class="container pl-lg-4 pr-lg-4"><div class="d-flex justify-content-between align-items-center text-muted ml-md-3 mr-md-3"><div class="footer-left"><p class="mb-0"> © 2023 <a href="https://twitter.com/username">Clinical Team</a>. <span data-toggle="tooltip" data-placement="top" title="Except where otherwise noted, the blog posts on this site are licensed under the Creative Commons Attribution 4.0 International (CC BY 4.0) License by the author.">Some rights reserved.</span></p></div><div class="footer-right"><p class="mb-0">Using the <a href="https://jekyllrb.com" target="_blank" rel="noopener">Jekyll</a> theme <a href="https://github.com/cotes2020/jekyll-theme-chirpy" target="_blank" rel="noopener">Chirpy</a>.</p></div></div></div></footer><div id="mask"></div><a id="back-to-top" href="#" aria-label="back-to-top" class="btn btn-lg btn-box-shadow" role="button"> <i class="fas fa-angle-up"></i> </a><div id="notification" class="toast" role="alert" aria-live="assertive" aria-atomic="true" data-animation="true" data-autohide="false"><div class="toast-header"> <button type="button" class="ml-2 ml-auto close" data-dismiss="toast" aria-label="Close"> <span aria-hidden="true">&times;</span> </button></div><div class="toast-body text-center pt-0"><p class="pl-2 pr-2 mb-3">A new version of content is available.</p><button type="button" class="btn btn-primary" aria-label="Update"> Update </button></div></div><script src="https://cdn.jsdelivr.net/npm/simple-jekyll-search@1.10.0/dest/simple-jekyll-search.min.js"></script> <script> SimpleJekyllSearch({ searchInput: document.getElementById('search-input'), resultsContainer: document.getElementById('search-results'), json: '/assets/js/data/search.json', searchResultTemplate: '<div class="pl-1 pr-1 pl-sm-2 pr-sm-2 pl-lg-4 pr-lg-4 pl-xl-0 pr-xl-0"> <a href="{url}">{title}</a><div class="post-meta d-flex flex-column flex-sm-row text-muted mt-1 mb-1"> {categories} {tags}</div><p>{snippet}</p></div>', noResultsText: '<p class="mt-5">Oops! No results found.</p>', templateMiddleware: function(prop, value, template) { if (prop === 'categories') { if (value === '') { return `${value}`; } else { return `<div class="mr-sm-4"><i class="far fa-folder fa-fw"></i>${value}</div>`; } } if (prop === 'tags') { if (value === '') { return `${value}`; } else { return `<div><i class="fa fa-tag fa-fw"></i>${value}</div>`; } } } }); </script> <script src="https://cdn.jsdelivr.net/combine/npm/magnific-popup@1.1.0/dist/jquery.magnific-popup.min.js,npm/lazysizes@5.3.2/lazysizes.min.js,npm/clipboard@2.0.11/dist/clipboard.min.js"></script> <script src="https://cdn.jsdelivr.net/combine/npm/dayjs@1.11.6/dayjs.min.js,npm/dayjs@1.11.6/locale/en.min.js,npm/dayjs@1.11.6/plugin/relativeTime.min.js,npm/dayjs@1.11.6/plugin/localizedFormat.min.js"></script> <script defer src="/assets/js/dist/post.min.js"></script> <script src="https://cdn.jsdelivr.net/npm/bootstrap@4.6.2/dist/js/bootstrap.bundle.min.js"></script> <script defer src="/app.js"></script> <script defer src="https://www.googletagmanager.com/gtag/js?id=G-L66SLQK23K"></script> <script> document.addEventListener("DOMContentLoaded", function(event) { window.dataLayer = window.dataLayer || []; function gtag(){dataLayer.push(arguments);} gtag('js', new Date()); gtag('config', 'G-L66SLQK23K'); }); </script>
